Pielotax

Pielotax is a peptide bioregulator from Professor Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, derived from kidney tissue. It is formulated to target renal aging — the progressive decline in glomerular filtration rate, tubular function, and renal reserve that accompanies human aging.

Age-related changes in the kidney (nephrosclerosis) include: glomerulosclerosis, tubulointerstitial fibrosis, reduced GFR (~1 mL/min/year after age 40), impaired tubular secretion, and diminished ability to respond to acid-base and volume challenges. These changes are accelerated by hypertension, diabetes, and chronic inflammation.

In the Khavinson bioregulator framework, Pielotax contains short regulatory peptides derived from kidney cortex tissue, proposed to interact with DNA and chromatin in renal cells to help maintain or restore youthful gene expression patterns. This would potentially support tubular cell maintenance, reduce fibrotic signaling, and preserve renal functional capacity in aging.

Like other Khavinson bioregulators, Pielotax is used as part of comprehensive multi-organ anti-aging protocols, often combined with cardiovascular bioregulators (Vesugen, Cardiogen), epithelial bioregulators (Chonluten, Bronchogen), and the flagship anti-aging peptides (Epithalon, Thymalin). The combination approach reflects the Khavinson group's view that systemic aging requires coordinated multi-organ bioregulatory intervention.